We have located links that may give you full text access.
Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple Negative Breast Cancer.
Oncologist 2020 October 25
BACKGROUND: In this phase II clinical trial, we evaluated the efficacy of the non-anthracycline combination of carboplatin and nab-paclitaxel in early stage triple negative breast cancer (TNBC).
PATIENTS AND METHODS: Patients with newly diagnosed stage II-III TNBC (N=69) were treated with neoadjuvant carboplatin (AUC 6) every 28 days x 4 plus nab-paclitaxel (100 mg/m2 ) weekly for 16 weeks. Pathological complete response (pCR) and residual cancer burden (RCB) were analyzed with germline mutation status, tumor infiltrating lymphocytes (TILs), TNBC molecular subtype, and GeparSixto immune signature (GSIS).
RESULTS: Sixty-seven patients were evaluable for safety and response. Fifty-three (79%) patients experienced grade 3/4 adverse events (AEs), including Grade 3 anemia (43%), neutropenia (39%), leukopenia (15%), thrombocytopenia (12%), fatigue (7%), peripheral neuropathy (7%), neutropenia (16%), and leukopenia (1%). Twenty-four patients (35%) had at least one dose delay and 50 patients (72%) required dose reduction. Sixty-three (94%) patients completed scheduled treatment. The responses were 32/67 (48%) pCR (RCB 0), 10/67 (15%) RCB I, 19/67 (28%) RCB II, 5/67 (7%) RCB III, and 1/67 (2%) progressed and had no surgery. Univariate analysis showed GSIS "immune-hot" and DNA repair defect (DRD) were associated with higher pCR with odds ratio of 4.62 (P=0.005) and 4.76 (P=0.03) respectively, and with RCB 0/I vs. RCB II/III with odds ratio 4.80 (P=0.01). "Immune-hot" GSIS was highly correlated with DRD status (P=0.03), TILs level (P<0.001), and TNBC molecular subtype (P<0.001). After adjusting for age, race, stage, and grade, GSIS remained associated with higher pCR and RCB class 0/I vs. II/III with odds ratio 7.19 (95% CI 2.01-25.68, P=0.002) and 8.95 (95%. CI 2.09-38.23, P=0.003), respectively.
CONCLUSIONS: The combination of carboplatin and nab-paclitaxel for early stage high risk TNBC showed manageable toxicity and encouraging anti-tumor activity. GSIS "immune-hot" signature is associated with higher pCR rate and RCB class 0/1. This study provides additional rationale for using non-anthracycline platinum-based therapy for future neoadjuvant trials in early stage TNBCs.
IMPLICATIONS FOR PRACTICE: Platinum is an important neoadjuvant chemotherapy agent for treatment of early stage triple negative breast cancer (TNBC). In this study, carboplatin and nab-paclitaxel were well tolerated and highly effective in TNBC, resulting in pathological complete response of 48%. In univariate and multivariate analyses adjusting for age, race, tumor stage and grade, "immune-hot" GeparSixto Immune Signature (GSIS) and DNA repair defect were associated with higher pCR and residual cancer burden class 0/1. The association of GSIS "immune-hot" signature with higher pCR holds promise for "de-escalating" neoadjuvant chemotherapy for patients with early stage TNBC. Although GSIS is not routinely used in clinic, further development of this immune signature into a clinically applicable assay is indicated.
PATIENTS AND METHODS: Patients with newly diagnosed stage II-III TNBC (N=69) were treated with neoadjuvant carboplatin (AUC 6) every 28 days x 4 plus nab-paclitaxel (100 mg/m2 ) weekly for 16 weeks. Pathological complete response (pCR) and residual cancer burden (RCB) were analyzed with germline mutation status, tumor infiltrating lymphocytes (TILs), TNBC molecular subtype, and GeparSixto immune signature (GSIS).
RESULTS: Sixty-seven patients were evaluable for safety and response. Fifty-three (79%) patients experienced grade 3/4 adverse events (AEs), including Grade 3 anemia (43%), neutropenia (39%), leukopenia (15%), thrombocytopenia (12%), fatigue (7%), peripheral neuropathy (7%), neutropenia (16%), and leukopenia (1%). Twenty-four patients (35%) had at least one dose delay and 50 patients (72%) required dose reduction. Sixty-three (94%) patients completed scheduled treatment. The responses were 32/67 (48%) pCR (RCB 0), 10/67 (15%) RCB I, 19/67 (28%) RCB II, 5/67 (7%) RCB III, and 1/67 (2%) progressed and had no surgery. Univariate analysis showed GSIS "immune-hot" and DNA repair defect (DRD) were associated with higher pCR with odds ratio of 4.62 (P=0.005) and 4.76 (P=0.03) respectively, and with RCB 0/I vs. RCB II/III with odds ratio 4.80 (P=0.01). "Immune-hot" GSIS was highly correlated with DRD status (P=0.03), TILs level (P<0.001), and TNBC molecular subtype (P<0.001). After adjusting for age, race, stage, and grade, GSIS remained associated with higher pCR and RCB class 0/I vs. II/III with odds ratio 7.19 (95% CI 2.01-25.68, P=0.002) and 8.95 (95%. CI 2.09-38.23, P=0.003), respectively.
CONCLUSIONS: The combination of carboplatin and nab-paclitaxel for early stage high risk TNBC showed manageable toxicity and encouraging anti-tumor activity. GSIS "immune-hot" signature is associated with higher pCR rate and RCB class 0/1. This study provides additional rationale for using non-anthracycline platinum-based therapy for future neoadjuvant trials in early stage TNBCs.
IMPLICATIONS FOR PRACTICE: Platinum is an important neoadjuvant chemotherapy agent for treatment of early stage triple negative breast cancer (TNBC). In this study, carboplatin and nab-paclitaxel were well tolerated and highly effective in TNBC, resulting in pathological complete response of 48%. In univariate and multivariate analyses adjusting for age, race, tumor stage and grade, "immune-hot" GeparSixto Immune Signature (GSIS) and DNA repair defect were associated with higher pCR and residual cancer burden class 0/1. The association of GSIS "immune-hot" signature with higher pCR holds promise for "de-escalating" neoadjuvant chemotherapy for patients with early stage TNBC. Although GSIS is not routinely used in clinic, further development of this immune signature into a clinically applicable assay is indicated.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app